
PACB Stock Forecast & Price Target
PACB Analyst Ratings
Bulls say
Pacific Biosciences of California Inc has demonstrated a positive financial trajectory, evidenced by an improved gross margin year-over-year, largely driven by a greater proportion of consumables revenue. The company has reported increased utilization of its Revio sequencing platform, reaching its highest levels since launch, which suggests robust demand for its products. Additionally, management anticipates sequential growth in Vega placements throughout the year, indicating a strong outlook for large-scale projects and overall business expansion.
Bears say
Pacific Biosciences of California Inc is facing a negative outlook due to an anticipated decline in gross margins, projected to fall below the 40.4% reported in the previous quarter. Additionally, there are concerns regarding stagnant utilization rates and weaker than expected demand for new instruments, potentially jeopardizing the company's financial targets for 2026. Furthermore, ongoing demand weakness in the critical market of China is expected to continue throughout 2023 and into 2024, further impacting the company's performance.
This aggregate rating is based on analysts' research of Pacific Biosciences of California and is not a guaranteed prediction by Public.com or investment advice.
PACB Analyst Forecast & Price Prediction
Start investing in PACB
Order type
Buy in
Order amount
Est. shares
0 shares